Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

Recent launches and approvals include the HeartWare ventricular assist system, Roche’s Elecsys HE4 assay for ovarian cancer and Coloplast’s Altis single-incision sling system.

You may also be interested in...



FDA Sticks Newly Approved HeartWare VAD With Unexpected Labeling Requirement

HeartWare International Inc.’s HeartWare Ventricular Assist System has finally gained PMA approval, but FDA labeling requirements have sparked questions from analysts.

FDA Panel Supports HeartWare VAD, Despite Trial Shortcomings

Benefits of HeartWare system, as well as the prospect of adding a competitive device to a market currently dominated by a single product, overshadow uncertainties from missing data, panelists vote.

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel